Purchase by Bentsur Ron of 330 shares of Nuvectis Pharma

NVCT Stock  USD 4.71  0.24  4.85%   
Slightly above 56% of all Nuvectis Pharma's private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Nuvectis Pharma suggests that some traders are interested. Nuvectis Pharma's investing sentiment can be driven by a variety of factors including economic data, Nuvectis Pharma's earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Nuvectis Pharma Inc director. General open market or private purchase of non-derivative or derivative security

Read at macroaxis.com
Nuvectis insider trading alert for perchase of common stock by Bentsur Ron, Chairman CEO, on 1st of June 2023. This event was filed by Nuvectis Pharma Inc with SEC on 2023-06-01. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Nuvectis Pharma's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Nuvectis Pharma's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Nuvectis Pharma Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Nuvectis Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Nuvectis Pharma Fundamental Analysis

We analyze Nuvectis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nuvectis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nuvectis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Book

Price To Book Comparative Analysis

Nuvectis Pharma is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Nuvectis Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Nuvectis Pharma stock to make a market-neutral strategy. Peer analysis of Nuvectis Pharma could also be used in its relative valuation, which is a method of valuing Nuvectis Pharma by comparing valuation metrics with similar companies.

Peers

Nuvectis Pharma Related Equities

DMACDiaMedica Therapeutics   5.23   
0%
84.0%
VCNXVaccinex   1.50   
0%
24.0%
VCYTVeracyte   1.23   
0%
19.0%
VANIVivani Medical   0.78   
0%
12.0%
DNTHDianthus Therapeutics   0.77   
0%
12.0%
VCELVericel Corp   0.63   
0%
10.0%
DOMHDominari Holdings   1.20   
19.0%
0%
DNLIDenali Therapeutics   2.53   
41.0%
0%
EQEquillium   4.11   
66.0%
0%
VALNValneva SE   6.16   
100.0%
0%

Additional Tools for Nuvectis Stock Analysis

When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.